ArticleJournal of virology1998
Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.Journal of virology · 2015Article
- Regulation of Sp100A subnuclear localization and transcriptional function by EBNA-LP and interferon.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2008Article
- Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp.Journal of virology · 2008Article
- Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.Journal of virology · 2006Article
- Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.Molecular and cellular biology · 2003Article
- EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.Journal of virology · 2003Article
- Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.Journal of virology · 2001Article
- Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.Journal of virology · 2000Article
- Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation.Oncogene · 2000Article
- Neoplastic transformation by Notch requires nuclear localization.Molecular and cellular biology · 2000Article
- A role for SKIP in EBNA2 activation of CBF1-repressed promoters.Journal of virology · 2000Article
- Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.Journal of virology · 2000Article
- Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.The American journal of pathology · 1999Article
- Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters.Journal of virology · 1999Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Epstein-Barr virus (EBV) EBNA2 protein is a transcriptional activator that regulates viral and cellular gene expression and is also essential for EBV-driven immortalization of B lymphocytes. The EBNA2-responsive enhancer in the viral latency C promoter (Cp) binds two cellular factors, CBF1 and CBF2. The precise role of the CBF2 protein for Cp enhancer function is presently unclear. CBF2 does not appear to interact with EBNA2 and binds just downstream of CBF1 between positions -339 and -368 in the Cp EBNA2 enhancer. Within this region an 8-bp sequence, CAGTGCGT, can be found, and a similar sequence is also located downstream of CBF1 binding sites in other EBNA2-responsive promoters. Previous studies have indicated that mutations and methylation in this sequence affect EBNA2 responsiveness. To investigate the requirements for CBF2 binding, we synthesized a series of oligonucleotides carrying double transversion mutations spanning both the conserved core sequence and outside flanking sequences. Surprisingly, mutations outside of the conserved core sequence in 4 bases immediately flanking the 5' end, GGTT, had the most deleterious effect on CBF2 binding. Mutations in the conserved core had a gradient effect, with those near the 5' end having the most deleterious effects on CBF2 binding. In addition, the affinities of CBF2 for binding to the LMP-1, LMP-2, and CD23 promoters were also measured. These promoters contain the conserved core but lack the 5' flanking GGTT motif and bound CBF2 weakly or not at all. Using Cp reporter plasmids containing CBF2 mutant binding sites, we were also able to show that at lower doses of EBNA2, Cp transactivation required a functional CBF2 binding site but that higher doses of EBNA2 transactivated CBF2 mutant promoters to 40% of wild-type levels. These assays indicate that CBF2 is important for EBNA2-mediated transactivation of the viral latency Cp. In addition, CBF2 activity was found to be associated with two polypeptides of 27 and 33 kDa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.